VEGF and bFGF gene polymorphisms in Polish patients with B-CLL

Wróbel, Tomasz; Mazur, Grzegorz; Dzietczenia, Justyna; Gebura, Katarzyna; Kuliczkowski, Kazimierz; Bogunia-Kubik, Katarzyna
March 2013
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
Academic Journal
Among a variety of angiogenic factors involved in the B cell chronic lymphocytic leukemia (B-CLL), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were identified. Their levels have been regarded as prognostic markers of the progression of disease. The objective of the present study was to assess whether polymorphisms located within the genes coding for these key angiogenic activators contribute to disease susceptibility and/or progression in patients with B-CLL. For this purpose, 180 individuals were investigated, including 68 B-CLL patients and 112 healthy controls. All individuals were typed for the VEGF (936 C > T) and bFGF (− 921 C > G) alleles using PCR-RFLP technique. Only a slight prevalence of the VEGF T variant was observed among patients as compared to healthy individuals ( p = 0.095) with a significant difference when high risk (stage III/IV) patients were considered (OR = 3.81, p = 0.045). No other significant association was observed between the VEGF polymorphism and progression of the disease. The VEGF alleles and genotypes segregated similarly in patients with different stage of the disease according to Rai classification. No significant relationships were also observed for the bFGF polymorphism with either susceptibility to B-CLL (when compared to control group) or progression of the disease. These results suggest the possible association of the VEGF polymorphism with high risk B-CLL.


Related Articles

  • Prognostic significance of vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer. Jang, Moon; Kim, Jong; Jeon, Young; Chong, So; Oh, Doyeun; Kim, Nam // International Journal of Clinical Oncology;Dec2013, Vol. 18 Issue 6, p1032 

    Background: Angiogenesis plays an important role in tumor development, progression, and metastasis. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis. However, the contribution of common VEGF polymorphisms to colorectal cancer (CRC) prognosis remains unclear. Methods:...

  • Vascular Endothelial Growth Factor A (VEGFA) Gene Polymorphisms Have an Impact on Survival in a Subgroup of Indolent Patients with Chronic Lymphocytic Leukemia. Lozano-Santos, Carol; Martinez-Velasquez, Jimena; Fernandez-Cuevas, Belen; Polo, Natividad; Navarro, Belen; Millan, Isabel; Garcia, Jose Miguel; Collado, Rosa; Sanchez-Godoy, Pedro; Carbonell, Felix; Garcia-Vela, Jose Antonio; Garcia-Marco, Jose Antonio; Gomez-Lozano, Natalia // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Vascular endothelial growth factor (VEGF)-mediated angiogenesis contributes to the pathogenesis of B-cell chronic lymphocytic leukaemia (CLL). We investigated the impact of VEGFA gene diversity on the clinical outcome of patients with this disease. A VEGFA haplotype conformed by positions...

  • Paeonol Oxime Inhibits bFGF-Induced Angiogenesis and Reduces VEGF Levels in Fibrosarcoma Cells. Hyo-Jeong Lee; Seung-Ae Kim; Hyo-Jung Lee; Soo-Jin Jeong; Ihn Han; Ji Hoon Jung; Eun-Ok Lee; Shudong Zhu; Chang-Yan Chen; Sung-Hoon Kim // PLoS ONE;2010, Vol. 5 Issue 8, p1 

    Background: We previously reported the anti-angiogenic activity of paeonol isolated from Moutan Cortex. In the present study, we investigated the negative effect of paeonol oxime (PO, a paeonol derivative) on basic fibroblast growth factor (bFGF)-mediated angiogenesis in human umbilical vein...

  • Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors. Tavakoli, Jahan; Aragon-Ching, Jeanny B. // Anti-Cancer Agents in Medicinal Chemistry;2010, Vol. 10 Issue 8, p593 

    No abstract available.

  • The Role of Vascular Endothelial Growth Factor A Polymorphisms in Breast Cancer. Doonyapat, Sa-nguanraksa; Pornchai, O-charoenrat // International Journal of Molecular Sciences;Nov2012, Vol. 13 Issue 11, p14845 

    Breast cancer is the most common cancer in females and the leading cause of cancer death in women worldwide. Angiogenesis, the formation of new blood vessels, plays an important role in the development and progression of breast cancer. Vascular endothelial growth factor A (VEGFA), the key...

  • Circulating sCD138 and Some Angiogenesis-Involved Cytokines Help to Anticipate the Disease Progression of Early-Stage B-Cell Chronic Lymphocytic Leukemia. Wołowiec, Dariusz; Dybko, Jarosław; Wróbel, Tomasz; Urbaniak-Kujda, Donata; Jaźwiec, Bożena; Tomaszewska-Toporska, Beata; Kapelko-Słowik, Katarzyna; Potoczek, Stanisław; Kuliczkowski, Kazimierz // Mediators of Inflammation;1/1/2006, Vol. 2006, Special section p1 

    Syndecan-1 (CD138) is a transmembrane heparin sulfate proteoglycan expressed on distinct stages of differentiation of B-lymphoid cells. Its prognostic value in B-cell chronic lymphocytic leukemia (B-CLL) has not been evaluated so far. The serum concentration of sCD138 and some...

  • Significance of Serum Connective Tissue Growth Factor in Patients with Hepatocellular Carcinoma and Relationship with Angiogenesis. Wang, Gui-Bo; Zhou, Xin-Yu; Yuan, Tao; Xie, Jun; Guo, Li-Ping; Gao, Ning; Wang, Xiao-Qin // World Journal of Surgery;Oct2010, Vol. 34 Issue 10, p2411 

    Background: Connective tissue growth factor (CTGF) expression changes variously in different human malignancies. The role of CTGF in hepatocellular carcinoma (HCC) is still not clear. The purpose of this study was to investigate the role of serum CTGF in patients with HCC and its correlation...

  • Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. Kraemer, Anja; Hauser, Stefan; Kim, Young; Gorschlüter, Marcus; Müller, Stefan C.; Brossart, Peter; Schmidt-Wolf, Ingo G. H. // GMS German Medical Science;2009, Vol. 7, p1 

    Background: The highly vascular nature of renal carcinoma cells suggests that inhibition of angiogenesis may be beneficial in this disease. Thalidomide has been described as inhibitor of the fibroblast growth factor (FGF) and the vascular endothelial growth factor (VEGF). Therefore and in...

  • Circulating Levels of VCAM and MMP-2 May Help Identify Patients with More Aggressive Prostate Cancer. De Cicco, Concetta; Ravasi, Laura; Zorzino, Laura; Sandri, Maria Teresa; Botteri, Edoardo; Verweij, Fabrizio; Granchi, Donatella; De Cobelli, Ottavio; Paganelli, Giovanni // Current Cancer Drug Targets;May2008, Vol. 8 Issue 3, p199 

    Background: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics